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economical benefit compared to conventional standard EBRT, 
with a saving of 98252.70€ in 75 treated patients. It also 
associates a time profit that may improve QoL. 
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Purpose/Objective: Rationale of accelerated partial breast 
irradiation (APBI) is the prevention of local relapse in breast 
area with the highest probability of recurrences in strictly 
selected patients. Intraoperative Radiotherapy (IORT) is one 
of the most promising techniques of APBI. The aim of this 
study is the preliminary evaluation of toxicity, cosmetic 
effect and 5-years rate of ipsilateral breast recurrences in 
patients treated with exclusive single dose IORT with 
electrons after quadrantectomy (QUAD) for early stage-breast 
cancer. 
Materials and Methods: Between January 2008 and June 
2014 thirty-one women were treated with single dose IORT in 
our Institution. Thirteen were enrolled into a multi-centric 
randomized trial (coordinated by Regina Elena Institute of 
Rome) and eighteen were treated with single dose for age 
and co-morbidities, that contraindicate external beam 
radiotherapy (EBRT). Patients underwent QUAD with sentinel 
lymph node biopsy. All of them were older than 60 years or in 
post-menopausal status, with a single tumour sized 2 cm or 
less, histological proven invasive ductal or lobular carcinoma 
and clinically N0. IORT was delivered with a mobile Linear 
Accelerator (NOVAC7 by SIT) with a total dose of 21 Gy. An 
electron energy 7 to 9 MeV was used. A perspex shield was 
placed under the mammary gland, to reduce dose to the 
chest wall, heart and ipsilateral lung. Acute and late 
toxicities were evaluated one month after the treatment, 
then every three months for two years and every six months 
up to 5 years, according to RTOG scale while cosmetic 
outcomes was assessed by Harvard criteria. 
Results: The median follow-up was 54,6 months (range 5 to 
78). Mean age of the patients was 72,5 years (range: 62-80). 
Pathologic findings identified twenty-six patients as 
infiltrating ductal carcinoma and 5 as infiltrating lobular 
carcinoma. Patients presented N0 or N1mic status, except for 
two cases with N1a, and negative surgical margins. Average 
diameter of applicators was 60 mm (range 40-80). Treatment 
was successfully completed in all patients with an average 
lengthening of the operative time of about 20 minutes. At the 
long follow-up only one woman presented local relapse after 
55 months from IORT; she underwent re-excision followed by 
EBRT. Acute toxicity was G0 in 19 patients, G1 in 8 cases and 
G2 in 4 patients. No G3/G4 toxicities occurred. As early side 
effects 6 patients experienced seromas and one patient 
complained wound healing difficulties. G1/G2 late toxicity 
occurred in 6 patients. No lung or heart toxicities were 
observed. Cosmetic valuation was excellent/good in 25 
patients; 6 cases were scored as fairy/poor. 
Conclusions: IORT with a single dose in early breast cancer is 
feasible and well tolerated technique. In our experience it 
resulted in a significant shortening of radiotherapy time and 
gain in quality of life in elderly patients. In eligible cases 
(according to age and clinical staging) it seems a valid 
treatment option for adjuvant radiotherapy.  
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Purpose/Objective: To evaluate local control and cosmetic 
outcome of intra-operative radiation therapy (IORT) as an 
exclusive treatment of early stage breast cancer in patients 
with criteria as GEC-ESTRO (good candidates). 
Materials and Methods: From October 2008 to December 
2013, 100 patients underwent wide breast cancer excision or 
quadrantectomy followed by IORT on tumor bed with 
accelerated electrons (Novac 7 NRT) at the dose of 21Gy. 
Patients were aging at least 50 years with unicentric, 
unifocal, pT1-2  
Results: The average age was 63.89 (range 50–89) with an 
average follow up of 33 months (range 6–65). The pathologic 
stage of the lesions resulted pT1 in 82 cases (82%), in 
particular: 5 cases pT1a (6,1% on 82 cases), 38 pT1b (46,3%) 
and 39 pT1c (47,6%); 11 cases (11%) was pT2 with a diameter 
of 2,5 cm. 
The Grading was G1 in 21 cases (21%), G2 in 59 cases (59%) 
and G3 in 13 cases (13%). The toxicity, evaluated according 
to the EORTC-RTOG criteria, was G0 (37%) in 37 cases, G1 
(48%) in 48 cases, G2 in 6 case (6%); only 2 was G3 (2%). We 
observed 9 case of lymphocele (9%); there were no infections 
of the surgical wound nor any mastitis, neither in the treated 
quadrant nor in the other ones. 
We observed a light fibrosis in 14 cases (14%), moderate in 9 
(9%) and liponecrosis in 10 cases (10%). As regards local 
control, there was 2 (2%) local relapse and 1 second tumor. 
The global survival was 100%. 
Cosmetic outcome, evaluated in four levels (Danoff and co.), 
was excellent in 17 cases (17%), good in 63 (63%), sufficient 
in 11 cases (11%), never insufficient. 
Conclusions: The IORT in early breast cancer, at the doses 
used in this study on patients according to GEC-ESTRO 
criteria, provided itself as a secure technique, repeatable, 
with good local control and cosmetic outcome.  
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Purpose/Objective: To describe the initial experience of the 
first institution in Portugal in treating early breast cancer 
with intraoperative radiotherapy (IORT) with an electronic 
brachytherapy system. 
Materials and Methods: We retrospectively analyzed the 
data of 30 women who underwent intraoperative irradiation 
during breast conserving surgery between April 2012 and 
November 2014. Treatment was performed in a single 
